Prise en charge thérapeutique des infections à herpèsvirus : traitements actuels et futurs

Lurain, 2010, Antiviral drug resistance of human cytomegalovirus, Clin Microbiol Rev, 23, 689, 10.1128/CMR.00009-10 De Clercq, 2013, Selective anti-herpesvirus agents, Antivir Chem Chemother, 23, 93, 10.3851/IMP2533 Piret, 2014, Antiviral drug resistance in herpesviruses other than cytomegalovirus, Rev Med Virol, 24, 186, 10.1002/rmv.1787 Prichard, 2014, The development of new therapies for human herpesvirus 6, Curr Opin Virol, 9, 148, 10.1016/j.coviro.2014.09.019 Mescalchin, 2011, Oligomeric nucleic acids as antivirals, Mol Basel Switz, 16, 1271 Campos, 2016, Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art, Rev Med Virol, 26, 161, 10.1002/rmv.1873 Sauerbrei, 2016, Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2, J Antimicrob Chemother, 71, 6, 10.1093/jac/dkv285 Boutolleau, 2009, Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection, Antiviral Res, 81, 174, 10.1016/j.antiviral.2008.11.003 Burrel, 2010, Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals, Antimicrob Agents Chemother, 54, 4833, 10.1128/AAC.00669-10 Chou, 2014, Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing, Antimicrob Agents Chemother, 58, 4697, 10.1128/AAC.03214-14 De, 2015, Herpes simplex virus and varicella zoster virus: recent advances in therapy, Curr Opin Infect Dis, 28, 589, 10.1097/QCO.0000000000000211 Whitley, 2014, A novel potential therapy for HSV, N Engl J Med, 370, 273, 10.1056/NEJMe1313982 McGuigan, 2009, FV100 as a new approach for the possible treatment of varicella-zoster virus infection, J Antimicrob Chemother, 64, 671, 10.1093/jac/dkp294 Migliore, 2010, FV-100: the most potent and selective anti-varicella zoster virus agent reported to date, Antivir Chem Chemother, 20, 107, 10.3851/IMP1472 Tyring, 2012, Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial, J Med Virol, 84, 1224, 10.1002/jmv.23329 Bonnafous, 2010, Activity of H2G on human herpesvirus-6B strains either sensitive or resistant to ganciclovir, J Clin Virol Off Publ Pan Am Soc Clin Virol, 48, 153, 10.1016/j.jcv.2010.03.019 Boutolleau, 2011, Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir, Antiviral Res, 91, 32, 10.1016/j.antiviral.2011.04.015 Melendez, 2015, Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus, Infect Drug Resist, 8, 269 Drouot, 2016, Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus, Antivir Ther, 10.3851/IMP3028 Boeckh, 2015, Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, 21, 24, 10.1016/j.bbmt.2014.11.002 Edlefsen, 2016, No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy, J Infect Dis, 10.1093/infdis/jiw129 Prichard, 2013, Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses, Antimicrob Agents Chemother, 57, 3518, 10.1128/AAC.00429-13 Coen, 2014, Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses, Antimicrob Agents Chemother, 58, 7312, 10.1128/AAC.03957-14 Cesarman, 2014, Gammaherpesviruses and lymphoproliferative disorders, Annu Rev Pathol, 9, 349, 10.1146/annurev-pathol-012513-104656 Green, 2001, Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg., 1, 103, 10.1034/j.1600-6143.2001.10202.x Ghosh, 2012, Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents, Blood, 119, 1008, 10.1182/blood-2011-06-362434 Perrine, 2007, A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies, Blood, 109, 2571, 10.1182/blood-2006-01-024703 Sbidian, 2013, Recalcitrant pseudotumoral anogenital herpes simplex virus type 2 in HIV-infected patients: evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy, Clin Infect Dis Off Publ Infect Dis Soc Am, 57, 1648, 10.1093/cid/cit592 Brennan, 2013, Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms, Rev Med Virol, 23, 97, 10.1002/rmv.1733 Leen, 2014, Antiviral T-cell therapy, Immunol Rev, 258, 12, 10.1111/imr.12138